.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.![]()
.``much of this delay in implementation can be attributed to the lack of coordination and cooperation between the city and county.''
.
please enter valid email